CIAM
FATE icon

Caitong International Asset Management’s Fate Therapeutics FATE Stock Holding History

Caitong International Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Buy
+1
New +$1 ﹤0.01% 2473
2025
Q1 		– Sell
-237
Closed -$391 – 2275
2024
Q4 		$391 Buy
+237
New +$597 ﹤0.01% 1497

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caitong International Asset Management's FATE Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Fate Therapeutics (FATE) in Q1 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #2473 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in FATE as recently as Q4 2024.

Caitong International Asset Management first reported a position in FATE in Q4 2024 and has held it in 2 quarters since. The position peaked at $391 in Q4 2024. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Caitong International Asset Management held 1 share of Fate Therapeutics worth $1 as of Q1 2026.
  • Fate Therapeutics was a new Caitong International Asset Management position in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2473 holding.
  • Caitong International Asset Management first reported a position in Fate Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • Caitong International Asset Management's Fate Therapeutics position peaked at $391 in Q4 2024.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.